Symetis is a Lausanne, Switzerland-based medical device company focused on transcatheter aortic valve implantation (TAVI) systems. Its lead product, Acurate TA™, is a self-aligning, nitinol stented tissue heart valve designed for trans-apical delivery, offering high positioning tolerance and ease of use. The company reported positive preliminary results from its first-in-man clinical study for Acurate TA™. Symetis is also developing Acurate TF™, a trans-femoral TAVI solution that is in pre-clinical validation and scheduled to enter clinical trials in 2011. The company raised CHF25M in equity financing to support commercial launch of its first product, clinical validation of Acurate TF™, and initiation of the US approval process. Board changes accompanied the financing, reflecting investor involvement in governance.

Total raised

$26M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2010